8-K: Current report filing
Published on October 25, 2001
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) October 24, 2001
-----------------------------------------------------------------
CYTOCLONAL PHARMACEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware 00-26078 75-2402409
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
2110 Research Row
Suite 621
Dallas, Texas 75235
(Address of principal executive
offices including zip code)
(214) 353-2922
(Registrant's telephone number,
including area code)
N.A.
(Former name or former address, if changed since last report)
Item 5. Other Events.
Effective October 24, 2001, Cytoclonal Pharmaceutics Inc. (the
"Company") changed its name to eXegenics Inc. This change was effected under
Delaware law in connection with the merger into the Company of its wholly owned
subsidiary, eXegenics Inc. In addition, effective October 24, 2001, the
Company's Nasdaq National Market symbol was changed to "EXEG." The information
contained in the Press Release dated October 24, 2001, which is attached hereto
as Exhibit 99.1, is incorporated herein by reference and the foregoing
description of such transactions contemplated thereby are qualified in their
entirety by reference to such exhibit.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
Exhibit No. Description
99.1 Press Release, dated October 24, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
CYTOCLONAL PHARMACEUTICS INC.
(Registrant)
Dated: October 25, 2001 By: /s/ Ronald Lane Goode, Ph. D.
---------------- -------------------------------------
Ronald Lane Goode, Ph.D.
President and Chief Executive Officer
EXHIBIT INDEX